Interleukin-1β and Risk of Premature Death in Patients With Myocardial Infarction

被引：38

作者：

Silvain, Johanne ^{[1
,2
,3
,4
]}

Kerneis, Mathieu ^{[1
,2
,3
,4
]}

Zeitouni, Michel ^{[1
,2
,3
,4
]}

Lattuca, Benoit ^{[1
,2
,3
,4
]}

Galier, Sophie ^{[2
,3
,4
]}

Brugier, Delphine ^{[1
,2
,3
,4
]}

Mertens, Emilie ^{[1
]}

Procopi, Niki ^{[1
]}

Suc, Gaspard ^{[1
]}

Salloum, Tomy ^{[1
]}

Frisdal, Eric ^{[2
,3
,4
]}

Le Goff, Wilfried ^{[2
,3
,4
]}

Collet, Jean-Philippe ^{[1
,2
,3
,4
]}

Vicaut, Eric ^{[5
]}

Lesnik, Philippe ^{[2
,3
,4
]}

Montalescot, Gilles ^{[1
,2
,3
,4
]}

Guerin, Maryse ^{[2
,3
,4
]}

机构：

[1] Sorbonne Univ, ACT Study Grp, ICAN Inst CardioMetab & Nutr,Inst Cardiol, INSERM,UMRS1166,Hop Pitie Salpetriere,AP HP, Paris, France

[2] Hop Pitie, INSERM, UMRSH66, Paris, France

[3] Sorbonne Univ, Paris, France

[4] Hop Pitie, ICAN Inst CardioMetab & Nutr, Paris, France

[5] Hop Fernand Widal, AP HP, ACT Study Grp, Unite Rech Clin, Paris, France

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 76卷 / 15期

关键词：

C-reactive protein; inflammation; interleukin-1; beta; mortality; myocardial infarction; C-REACTIVE PROTEIN; CORONARY-ARTERY-DISEASE; HEART-FAILURE; INFLAMMATION; ATHEROSCLEROSIS; ASSOCIATION; REDUCTION; MORTALITY; MARKERS;

D O I：

10.1016/j.jacc.2020.08.026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Inhibition of the interleukin (IL)-1 beta innate immunity pathway is associated with anti-inflammatory effects and a reduced risk of recurrent cardiovascular events in stable patients with previous myocardial infarction (MI) and elevated high-sensitivity C-reactive protein (hs-CRP). OBJECTIVES This study assessed the association between IL-1 beta level with all-cause mortality in patients with acute ST-segment elevation MI who underwent primary percutaneous coronary intervention and the interplay between IL-1 beta and hs-CRP concentrations on the risk of premature death. METHODS IL-1 beta concentration was measured in 1,398 patients with ST-segment elevation MI who enrolled in a prospective cohort. Crude and hazard ratios for all-cause and cardiovascular mortality were analyzed at 90 days and 1 year using multivariate Cox proportional regression analysis. Major adverse cardiovascular events (MACEs) were analyzed. RESULTS IL-1 beta concentration measured at admission was associated with all-cause mortality at 90 days (adjusted hazard ratio [adjHR]: 1.47 per 1 SD increase; 95% confidence interval [CI]: 1.16 to 1.87; p < 0.002). The relation was nonlinear, and the highest tertile of IL-1 beta was associated with higher mortality rates at 90 days (adjHR: 2.78; 95% CI: 1.61 to 4.79; p = 0.0002) and at 1 year (adjHR: 1.93; 95% CI: 1.21 to 3.06; p = 0.005), regardless of the hs-CRP concentration. Significant relationships were equally observed when considering cardiovascular mortality and MACEs at 90 days (adjHR: 2.42; 95% CI: 1.36 to 4.28; p = 0.002, and adjHR: 2.29; 95% CI: 1.31 to 4.01; p = 0.004, respectively) and at 1 year (adjHR: 2.32; 95% CI: 1.36 to 3.97; p = 0.002, and adjHR: 2.35; 95% CI: 1.39 to 3.96; p = 0.001, respectively). CONCLUSIONS IL-1 beta measured at admission in patients with acute MI was independently associated with the risk of mortality and recurrent MACEs. (C) 2020 by the American College of Cardiology Foundation.

引用

页码：1763 / 1773

页数：11

共 26 条

[1] Interleukin-1 blockade in cardiovascular diseases: a clinical update [J].